Jacques Leibowitch (August 1, 1942–March 4, 2020) was a French immunologist, nephrologist and clinical researcher whose work helped shape the understanding and treatment of HIV and AIDS. In 1982, he proposed that a CD4-targeting retrovirus might cause the epidemic, a hypothesis that helped direct French researchers toward the virus later identified as HIV.
After studying medicine in Paris, Leibowitch trained in clinical immunology at the Necker Hospital and conducted research in cellular immunology at Harvard Medical School from 1970 to 1972. He later studied human complement biology at London’s Royal Hammersmith Hospital and completed senior training in nephrology. In 1980, he joined Raymond Poincaré Hospital in Garches as an immunology assistant lecturer.
Working with Dominique Mathez, Leibowitch developed laboratory methods to detect HIV and measure active virus in patients. Their work helped identify contaminated blood donations and showed that the effects of AZT used alone were limited and temporary. Leibowitch later pioneered triple-drug treatment in Europe, combining antiviral medicines to control HIV over the long term.
From 2003 to 2014, he led the ICCARRE treatment program, exploring whether people whose HIV was controlled could take antiviral medication fewer days each week than standard regimens prescribed. He also wrote Un virus étrange venu d'ailleurs and Pour en finir avec le sida.